Development and characterization of polo-like kinase 2 loaded nanoparticles-A novel strategy for (serine-129) phosphorylation of alpha-synuclein
Rodríguez-Nogales C 1, Garbayo E 2, Martínez-Valbuena I 3, Sebastián V 4, Luquin MR (5), Blanco-Prieto MJ 6.
(1) Pharmacy and Pharmaceutical Technology Department, University of Navarra, Pamplona, Spain.
(2) Pharmacy and Pharmaceutical Technology Department, University of Navarra, Pamplona, Spain; Instituto de Investigación Sanitaria de Navarra (IDISNA), Pamplona, Spain.
(3) Department of Neurology, Clínica Universidad de Navarra, Pamplona, Spain.
(4) Chemical & Environmental Engineering Department & Nanoscience Institute of Aragon, University of Zaragoza, Zaragoza, Spain; Networking Research Center on Bioengineering, Biomaterials and Nanomedicine, CIBER-BBN, Madrid, Spain.
(5) Instituto de Investigación Sanitaria de Navarra (IDISNA), Pamplona, Spain; Department of Neurology, Clínica Universidad de Navarra, Pamplona, Spain.
(6) Pharmacy and Pharmaceutical Technology Department, University of Navarra, Pamplona, Spain; Instituto de Investigación Sanitaria de Navarra (IDISNA), Pamplona, Spain
Revisão:International Journal of Pharmaceutics
Data: 30/Nov/2016Neurologia [ES]
Polo like kinase 2 (PLK2), a serine/threonine serum inducible kinase, has been proposed to be the major factor responsible for phosphorylating alpha-synuclein (α-syn) at Serine-129 (Ser-129) in Parkinson's disease (PD).
A suitable strategy to gain insights into PLK2's biological effects might be to increase PLK2 intracellular levels with the aim of reproducing the slow progressive neuronal changes that occur in PD.
The goal of this study was to develop and characterize a novel drug delivery system (DDS) for PLK2 cytosolic delivery using Total recirculating one machine system (TROMS), a technique capable of encapsulating fragile molecules while maintaining their native properties.
A protocol for nanoparticle (NP) preparation using TROMS was set up. NPs showed a mean diameter of 257±15.61nm and zeta potential of -16±2mV, suitable for cell internalization. TEM and SEM images showed individual, spherical, dispersed NPs. The drug entrapment efficacy was 61.86±3.9%. PLK2-NPs were able to enter SH-SY5Y cells and phosphorylate α-syn at Ser-129, demonstrating that the enzyme retained its activity after the NP manufacturing process.
This is the first study to develop a DDS for continuous intracellular delivery of PLK2. These promising results indicate that this novel nanotechnology approach could be used to elucidate the biological effects of PLK2 on dopaminergic neurons.
CITAÇÃO DO ARTIGO Int J Pharm. 2016 Nov 30;514(1):142-149. doi: 10.1016/j.ijpharm.2016.06.044
A Clínica é o hospital privado com maiores recursos tecnológicos de Espanha, tudo num único centro.
Os profissionais da Clínica realizam um trabalho contínuo de investigação e formação, sempre em benefício do paciente.
Conheça porque é que somos diferentes em relação a outros centros sanitários. Qualidade, rapidez, comodidade e resultados.